Comprehensive Characterization of Nanosized Extracellular
Vesicles from Central and Peripheral Organs: Implications for Preclinical
and Clinical Applications
posted on 2020-08-24, 19:11authored bySubhash Chand, Ala Jo, Neetha Nanoth Vellichirammal, Austin Gowen, Chittibabu Guda, Victoria Schaal, Katherine Odegaard, Hakho Lee, Gurudutt Pendyala, Sowmya V. Yelamanchili
Extracellular
vesicles (EVs) are nanosized vesicles that have been
garnering a lot of attention for their valuable role as potential
diagnostic markers and therapeutic vehicles for a plethora of pathologies.
While EV markers from biofluids such as plasma, serum, urine, cerebrospinal
fluid, and in vitro cell culture-based platforms
have been extensively studied, a significant knowledge gap that remains
is the characterization of specific organ-derived EVs (ODE). Here,
we present a standardized protocol for isolation and characterization
of purified EVs isolated from brain, heart, lung, kidney, and liver
from rat and postmortem human tissue. Next, using quantitative mass
spectrometry-based proteomics, we characterized the respective tissue
EV proteomes that identified synaptophysin, caveolin-3, solute carrier
family 22 member 2, surfactant protein B, and fatty acid-binding protein
1 as potential markers for the brain, heart, kidney, lung, and liver
EV, respectively. These respective tissue-specific markers were further
validated using both immunoblotting and a nanoplasmonic platform single
EV imaging analysis in the two species. To summarize, our study for
the first time using traditional biochemical and high-precision technology
platforms provides a valuable proof-of-concept approach in defining
specific ODE markers, which could further be developed as potential
therapeutic candidates for respective end organ-associated pathologies.